Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease

Abstract

Key Points Regadenoson did not reduce iNKT cell activation to a prespecified level when administered to patients with SCD. Because iNKT cell activation was not reduced, the benefit of iNKT cell-based therapies in SCD cannot be determined.</jats:p